BGC 201259

Drug Profile

BGC 201259

Alternative Names: BGC 20-1259; RS 1259

Latest Information Update: 30 Apr 2009

Price : $50

At a glance

  • Originator BTG
  • Developer BTG; SAFC Pharma
  • Class Antidementias
  • Mechanism of Action Acetylcholinesterase inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in Sweden (PO)
  • 30 May 2007 Interim results from a multiple-dose phase I trial in elderly and young volunteers added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top